David Vicente

8.9k total citations · 1 hit paper
30 papers, 726 citations indexed

About

David Vicente is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Physiology. According to data from OpenAlex, David Vicente has authored 30 papers receiving a total of 726 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 4 papers in Physiology. Recurrent topics in David Vicente's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Diagnosis and Treatment (6 papers) and Gastric Cancer Management and Outcomes (4 papers). David Vicente is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Diagnosis and Treatment (6 papers) and Gastric Cancer Management and Outcomes (4 papers). David Vicente collaborates with scholars based in Spain, United States and United Kingdom. David Vicente's co-authors include Luis Paz‐Ares, Corinne Faivre‐Finn, Rina Hui, Mustafa Özgüroğlu, David R. Spigel, Ki Hyeong Lee, Scott Antonia, Shuji Murakami, Davey B. Daniel and Phillip A. Dennis and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

David Vicente

29 papers receiving 716 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

2019 305 citations Jhanelle E. Gray, Augusto Villegas et al. Journal of Thoracic Oncology profile →

Peers

Countries citing papers authored by David Vicente

Since Specialization

Citations

This map shows the geographic impact of David Vicente's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Vicente with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Vicente more than expected).

Fields of papers citing papers by David Vicente

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Vicente. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Vicente. The network helps show where David Vicente may publish in the future.

Co-authorship network of co-authors of David Vicente

This figure shows the co-authorship network connecting the top 25 collaborators of David Vicente. A scholar is included among the top collaborators of David Vicente based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Vicente. David Vicente is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Did high frequency phone surveys during the COVID-19 pandemic include disability questions? An assessment of COVID-19 surveys from March 2020 to December 2022 2024 ·BMJ Open ·(unknown), David Vicente, Sophie Mitra, Douglas Teodoro, Minerva Rivas Velarde	1
2	Evaluation of Nutritional Interventions in the Care Plan for Cancer Patients: The NOA Project 2023 ·Nutrients ·Pedro Pablo García‐Luna, (unknown), (unknown), (unknown), Pablo Remón-Ruiz, Francisco José Sánchez-Torralvo, Jerónimo Pachón, (unknown), (unknown), Javier Salvador Bofill, David Vicente, Gabriel Olveira	1
3	Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study. 2023 ·Journal of Clinical Oncology ·James Chih‐Hsin Yang, (unknown), Jong Seok Lee, Yun Fan, Filippo de Marinis, Isamu Okamoto, Takako Inoue, (unknown), Zhang Li, Cheng‐Ta Yang, Emmanuel de la Mora Jimenez, Jianying Zhou, M. Pérol, Ki Hyeong Lee, David Vicente, Eiki Ichihara, Gregory J. Riely, Yiwen Luo, Niyati Bhagwati, Shun Lü	50
4	Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial 2022 ·ESMO Open ·Suresh Senan, Mustafa Özgüroğlu, Davey B. Daniel, Augusto Villegas, David Vicente, Shuji Murakami, Rina Hui, Corinne Faivre‐Finn, Luis Paz‐Ares, Yi‐Long Wu, Helen Mann, Phillip A. Dennis, S. Antonia	14
5	Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma 2021 ·Neuro-Oncology Advances ·Mustafa Khasraw, Michael Weller, David Lorente, Kathryn S. Kolibaba, Chee Khoon Lee, Craig Gedye, Macarena I. de la Fuente, David Vicente, David A. Reardon, Hui Gan, Andrew M. Scott, Isabelle Dussault, Christoph Helwig, Laureen S. Ojalvo, (unknown), Morris D. Groves	18
6	Role of Brown and Beige Adipose Tissues in Seasonal Adaptation in the Raccoon Dog (Nyctereutes procyonoides) 2021 ·International Journal of Molecular Sciences ·(unknown), Kari A. Mäkelä, Shivaprakash Jagalur Mutt, (unknown), Anna Kaisanlahti, David Vicente, Tommi Noponen, Anu Autio, Anne Roivainen, Pirjo Nuutila, Seppo Saarela, Karl‐Heinz Herzig	5
7	SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020) 2021 ·Clinical & Translational Oncology ·Ernest Nadal, Joaquim Bosch‐Barrera, S. Cedrés, (unknown), Rosario García‐Campelo, M. Guirado, Rafael López Castro, Ana Laura Ortega Granados, David Vicente, Javier de Castro	18
8	Lack of collagen XVIII leads to lipodystrophy and perturbs hepatic glucose and lipid homeostasis 2020 ·The Journal of Physiology ·(unknown), David Vicente, Kari A. Mäkelä, Mikko Finnilä, Ilkka Miinalainen, Jarkko Koivunen, Valerio Izzi, Mari Aikio, Sanna‐Maria Karppinen, (unknown), Jérôme Thevenot, Karl‐Heinz Herzig, Ritva Heljäsvaara, Taina Pihlajaniemi	14
9	1272P Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC) 2020 ·Annals of Oncology ·Luis Paz‐Ares, (unknown), David Vicente, Enriqueta Felip, Daniel Lee, K.H. Lee, C-C. Lin, M.J. Flor, Massimo Di Nicola, Rosa Álvarez, Christoph Helwig, Laureen S. Ojalvo, (unknown), Byoung Chul Cho	1
10	Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC) 2020 ·Lung Cancer ·Corinne Faivre‐Finn, David R. Spigel, Suresh Senan, Corey J. Langer, Bradford A. Perez, Mustafa Özgüroğlu, Davey B. Daniel, Augusto Villegas, David Vicente, Rina Hui, Shuji Murakami, Luis Paz‐Ares, Helen Broadhurst, Catherine Wadsworth, Phillip A. Dennis, Scott Antonia	31
11	Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC breakdown → 2019 ·Journal of Thoracic Oncology ·Jhanelle E. Gray, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Byoung Chul Cho, David Planchard, Luis Paz‐Ares, Corinne Faivre‐Finn, Johan Vansteenkiste, David R. Spigel, Catherine Wadsworth, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu, Scott Antonia	305
12	Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer 2019 ·Anti-Cancer Drugs ·Ignacio Romero, (unknown), Ana Santaballa, (unknown), (unknown), Santiago González-Santiago, Antonio Casado, David Vicente, Eugenia Ortega, Ana Herrero, Eva Guerra, Pilar Barretina-Ginesta, María Jesús Rubio, Alejandro Martínez, Isabel Bover, Laura Vidal, Àngels Arcusa, (unknown), Yolanda García García, Antonio González-Martı́n	9
13	ASTRIS: A Global Real-World Study of Osimertinib in >3000 Patients with EGFR T790M Positive Non-Small-Cell Lung Cancer 2019 ·Future Oncology ·Filippo de Marinis, Yi‐Long Wu, Gilberto de Castro, Gee‐Chen Chang, Yuh-Min Chen, Byoung Chul Cho, H. Freitas, Liyan Jiang, Sang-We Kim, Claudio Martín, Giulio Metro, Mariano Provencio, Johan Vansteenkiste, David Vicente, Qing Zhou, (unknown), Nicolaas A. Bakker, James R. Rigas, Parneet Cheema	40
14	MA02.03 ASTRIS: A Real World Treatment Study of Osimertinib in Patients with EGFR T790M-Positive NSCLC 2018 ·Journal of Thoracic Oncology ·Yi‐Long Wu, Byoung Chul Cho, Qing Zhou, Gee‐Chen Chang, Liyan Jiang, Giulio Metro, Claudio Martín, Gilberto de Castro, Johan Vansteenkiste, David Vicente, A. Milner, James R. Rigas, (unknown), Mariano Provencio	1
15	ASTRIS global real world study of osimertinib in patients (pts) with EGFR T790M non-small cell lung cancer (NSCLC): Subpopulation analyses 2018 ·Annals of Oncology ·Mariano Provencio, Parneet Cheema, Johan Vansteenkiste, Byoung Chul Cho, Caicun Zhou, Jinming Yu, Claudio Martín, (unknown), Yong He, Yanping Hu, David Vicente, Michele Miranda, James R. Rigas, Filippo de Marinis	1
16	Evaluation of intraoperative analgesia provided by incisional lidocaine and bupivacaine in cats undergoing ovariohysterectomy 2017 ·Journal of Feline Medicine and Surgery ·David Vicente, Annika Bergström	14
17	SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016) 2016 ·Clinical & Translational Oncology ·Andrés Poveda, Virginia Martínez, César Serrano, Isabel Sevilla, María José Lecumberri, Robert Díaz Beveridge, Anna Estival, David Vicente, (unknown), Javier Martín‐Broto	16
18	Involvement of host cell heparan sulfate proteoglycan inTrypanosoma cruziamastigote attachment and invasion 2011 ·Parasitology ·(unknown), (unknown), Cláudia M. Calvet, David Vicente, Leny Toma, Marco Aurélio Krieger, (unknown), Mirian Cláudia de Souza Pereira	23
19	PHASE II STUDY OF HYPOFRACTIONATED RADIOTHERAPY (HYPORT) IN LOCALISED PROSTATE CANCER: REPORT ON ACUTE AND 18 MONTH LATE TOXICITY 2008 ·European Urology Supplements ·(unknown), David Macías, D. González, David Gallardo, (unknown), (unknown), David Vicente, David Gutiérrez Abad, (unknown), (unknown), Dolores Prats	1
20	First efficacy assessment of a phase II study with cyclophosphamide, vincristine, liposomal doxorubicin, and prednisone plus rituximab, administered every two weeks (R-COMP-14) as primary treatment for NHL 2007 ·Journal of Clinical Oncology ·(unknown), José Gómez‐Codina, Mariano Provencio, A. Rueda, Marta Llanos, (unknown), David Vicente, P. Sabín, (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact